✦ LIBER ✦

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting

✍ Scribed by Pierre N. Tariot; Jeffrey L. Cummings; Ira R. Katz; Jacobo Mintzer; Carlos A. Perdomo; Elias M. Schwam; Edward Whalen

Book ID: 109128207
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 249 KB
Volume: 49
Category: Article
ISSN: 0002-8614
DOI: 10.1111/j.1532-5415.2001.49266.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of donepezil in pati

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

✍ Howard Feldman; Serge Gauthier; Jane Hecker; Bruno Vellas; Yikang Xu; John R. Ie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

## Abstract ## Background There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in __post hoc__ analyses of a subgroup of patients with more severe AD (standardized Mi

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study

✍ Vee. P. Prasher; Adam Huxley; M. S. Haque 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. ## Method This

A randomized, placebo-controlled study o

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil

✍ Sanford I. Finkel; Jacobo E. Mintzer; Maurice Dysken; K. R. R. Krishnan; Tal Bur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## Objective To examine the safety and efficacy of sertraline augmentation therapy in the treatment of behavioral manifestations of Alzheimer's disease (AD) in outpatients treated with donepezil. ## Methods and materials Patients with probable or possible AD, and a Neuropsychiatric I

Cerebrolysin in Alzheimer's disease: a r

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

✍ M. Panisset; S. Gauthier; H. Moessler; M. Windisch; and The Cerebrolysin Study G 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 103 KB

Efficacy and safety of bisacodyl in the

Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study

✍ S. KIENZLE-HORN; J.-M. VIX; C. SCHUIJT; H. PEIL; C. C. JORDAN; M. A. KAMM 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre